Ahmad Naim

The employee absenteeism costs of inflammatory bowel disease: evidence from US National Survey Data.

Objective: To estimate indirect costs associated with inflammatory bowel disease (IBD). Methods: This was a retrospective study using 1996 to 2006 US Medical Expenditure Panel Survey data. Employed individuals were aged 18 to 64 years. A two-part model estimated the probability of time lost from work because of illness and the annual number of workdays missed. Results: A total of 71.5% (143/200) and 58.2% (52,257/89,846) of individuals with and without IBD, respectively, missed time from work because of illness (P = 0.0001). Among individuals who missed work, those with IBD missed more workdays annually than those without IBD ( = 13.38, 9.89, respectively; P = 0.044). Incremental per capita cost in annual lost workdays between those with and without IBD was

Adjusting for comorbidities in cost of illness studies

783. National indirect IBD-related costs were

Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.

249 million annually. Conclusions: Individuals with IBD have higher probabilities of missing time from work and missing workdays than those without IBD.

The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data.

Abstract Motivation: Differences in cost of illness (COI) methodological approaches have led to disparate results. This analysis examines two sources of this variation: specification of comorbidities in the estimated cost models and assumed prevalence rates used for generating aggregate costs. The study provides guidance in determining which comorbidities are important to include and how to handle uncertainty in optimal model specification and prevalence rate assumptions. Methods: Comorbidities are categorized into four types. Type I comorbidities are those that increase the risk of the disease of interest; Type II comorbidities have no causal link to the disease of interest but are, nonetheless, highly correlated with that disease; Type III comorbidities are illnesses that the disease of interest may cause, and Type IV are comorbidities that have no causal link to the disease of interest and are only weakly correlated with that disease. Two-part models are used to estimate the direct costs of rheumatoid arthritis and diabetes mellitus using 2000–2007 Medical Expenditure Panel Survey data. Results: COI estimates are sensitive to the specification of comorbidities. The odds of incurring any expenses varies by 71% for diabetes mellitus and by 27% for rheumatoid arthritis, while conditional expenditures (e.g., expenditures among subjects incurring at least some expenditures) vary by 62% and 45%, respectively. Uncertainty in prevalence rates cause costs to vary. A sensitivity analysis estimated the COI for diabetes ranges from

Work absences and expenditures for employees with autoimmune inflammatory diseases.

131.7–

The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey

172.0 billion, while rheumatoid arthritis varies from

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

12.8–

Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making

26.2 billion. Conclusions: The decision to include Type II and Type III comorbidities is crucial in COI studies. Alternative models should be included with and without the Type III comorbidities to gauge the range of cost effects of the disease. In generating costs, alternative values for prevalence rates should be used and a sensitivity analysis should be performed.

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

This analysis of the myeloproliferative neoplasm (MPN) Landmark survey evaluated gaps between patient perceptions of their disease management and physician self‐reported practices.

Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review

Objective: To estimate indirect costs associated with rheumatoid arthritis (RA). Methods: This was a retrospective study using 1996–2006 US Medical Expenditure Panel Survey data. Employed individuals were aged 18 to 65 years. A two-part model estimated the probability of time lost from work and annual number of workdays missed due to illness. Results: Sixty-seven percent (209/312) of RA individuals missed work versus 58% (52,046/89,734) of those without RA (P = 0.0007). Among individuals who missed work, those with RA missed more workdays annually than those without RA ( = 13.659, 9.879, respectively; P = 0.008). Incremental per capita costs in annual lost workdays between those with and without RA were